All In Biotech

Free tool

FAERS Monitor: Idacio

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761255 or its brand name (Idacio, Adalimumab-Aacf). Reports on generic versions are filed under their own applications.

Reports

335

Serious

270

81% of reports

Hospitalization

163

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea32
  • psoriatic arthropathy32
  • abdominal pain20
  • drug ineffective19
  • haematochezia18
  • off label use18
  • injection site pain15
  • arthralgia14
  • fatigue13
  • vomiting13
  • crohn^s disease12
  • frequent bowel movements12
  • influenza like illness12
  • nasopharyngitis12
  • product dose omission issue12

Reports by year received

View as table
YearReports
20201
20214
20224
202334
202473
2025129
202690

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,824 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
psoriatic arthropathySignal3249.535.61,475
frequent bowel movementsSignal1227.916.0285
haematocheziaSignal1820.513.1315
influenza like illnessSignal129.25.380
abdominal painSignal205.43.568
nasopharyngitisSignal124.12.325
diarrhoeaSignal323.12.245
injection site painSignal153.11.919
product dose omission issueSignal122.61.510
arthralgiaSignal142.11.37
vomiting131.71.03
off label use181.30.81
fatigue131.00.60
drug ineffective190.90.60
crohn^s disease120.00.0692,628

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.